Peptide · Fact sheet
Ziconotide
Also known as Prialt · SNX-111
Ziconotide is FDA approved as Prialt for severe chronic pain in people who need intrathecal therapy and cannot tolerate or do not respond to other treatment. It is not a routine pain supplement and has a boxed warning for severe psychiatric and neurologic effects.
What is Ziconotide?
Ziconotide is a synthetic version of a 25-amino-acid conopeptide originally identified in cone-snail venom.
It blocks N-type calcium channels involved in pain signaling and is delivered into the fluid around the spinal cord through specialist equipment.
Benefits people look for
It shows that a venom-derived peptide can become a non-opioid medicine for otherwise difficult pain.
Its narrow delivery setting and serious central nervous system effects are as important as its novel mechanism.
What the evidence supports
- Controlled trials found greater average pain reduction than placebo in selected people with severe refractory pain.
- It is not an opioid and does not work through opioid receptors, which makes its mechanism clinically distinctive.
All research areas
- Severe chronic noncancer pain
- Cancer- and AIDS-related pain
- Non-opioid spinal pain signaling
- Other highly selected pain settings under specialist research
Anecdotal reports & lived experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens.
No attributable personal reports are summarized here yet. The benefits above describe research interests; the side effects below come from the cited medical sources.
We do not fill this gap with unsourced testimonials or estimated success rates.
Side effects & risks
- The boxed warning describes severe psychiatric symptoms and neurologic impairment; people with a history of psychosis should not receive Prialt.
- Confusion, hallucinations, mood or consciousness changes, dizziness, gait problems, memory impairment, nausea, and other neurologic effects can occur.
- Intrathecal equipment introduces risks such as meningitis and catheter or pump complications.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research: how strong is it?
Strong human evidence for approved usesRandomized placebo-controlled trials support analgesic benefit in selected severe-pain populations. Adverse effects and the need for specialist intrathecal delivery sharply limit generalization.
Selected research to read
Placebo-controlled study of analgesic benefit and neurologic adverse effects.
Controlled trial illustrating both pain reduction and substantial adverse effects with faster escalation.
FDA approval & research status
Prialt is FDA approved for severe chronic pain in patients for whom intrathecal therapy is warranted and who are intolerant of or refractory to other treatment.
Approved uses covered here
- Management of severe chronic pain when intrathecal therapy is warranted and other treatment is ineffective or not tolerated
FDA approved for severe chronic pain by a specific route
Ziconotide is approved under the Prialt label for intrathecal treatment of severe chronic pain in a narrow clinical context, not as a general pain remedy.
This summarizes the cited product or research record. Trial phases do not establish successful completion of earlier stages, and a stopped program is not ongoing development. Approval applies only to the labeled product, use and population.
What we still don’t know
- Which patients can obtain durable benefit without unacceptable neurologic effects
- Long-term comparative outcomes versus other specialist pain approaches
- How trial averages translate across different causes of severe pain
The takeaway
Ziconotide is a striking peptide success story, but not a casual one: its benefit belongs to a narrow, specialist pain setting with serious neuropsychiatric and device-related risks.
Sources & further reading
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- 1fdaFDA prescribing information: Prialt
Official indication, boxed warning, safety information, and clinical-study summary.
- 2pubmedRandomized trial in severe chronic pain
Placebo-controlled study of analgesic benefit and neurologic adverse effects.
- 3pubmedRandomized trial in chronic nonmalignant pain
Controlled trial illustrating both pain reduction and substantial adverse effects with faster escalation.